MetaCap

Replimune Group Balance Sheet

NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

19.07-0.16 (-0.83%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Replimune Group financial position

At the end of fiscal 2026, Replimune Group reported total assets of $332.4 million, down 39.7% from a year earlier against total liabilities of $166.2 million. Shareholders' equity stood at $166.2 million, or 50.0% of assets. The company held $209.0 million in cash and equivalents against $83.3 million of debt, a net cash position of $125.7 million.

The current ratio (current assets divided by current liabilities) was 4.79, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.50.

Summary generated from market data by MetaCap's automated system. Methodology

Replimune Group balance sheet (annual)

Replimune Group annual balance sheet
Fiscal year (USD)FY 20262026-03-31FY 20252025-03-31FY 20242024-03-31FY 20232023-03-31FY 20222022-03-31FY 20212021-03-31FY 20192020-03-31FY 20192019-03-31FY 20182018-03-31FY 20172017-03-31
Cash & Equivalents209.02M111.12M74.46M146.59M105.95M182.52M59.50M25.70M17.58M20.67M
Short-Term Investments59.87M372.69M346.21M436.80M289.71M293.78M109.06M109.11M43.97M—
Inventory0—————————
Total Current Assets279.12M495.88M433.67M592.60M403.98M483.75M174.25M140.98M64.70M—
Property, Plant & Equipment12.97M13.74M10.48M7.48M7.93M7.44M6.86M12.16M370.00K—
Total Assets332.39M551.33M487.72M646.59M461.19M543.10M234.10M154.33M65.15M—
Accounts Payable6.67M12.46M2.58M5.36M3.73M2.35M3.43M7.08M1.99M—
Total Current Liabilities58.23M62.36M40.44M33.83M20.76M14.55M11.87M9.88M5.16M—
Long-Term Debt83.31M46.38M44.81M28.65M0—9.80M———
Total Liabilities166.23M135.49M113.21M91.30M49.96M44.37M50.38M16.47M6.86M—
Shareholders' Equity166.16M415.84M374.51M555.29M411.23M498.73M183.72M137.86M-28.07M-11.52M
Retained Earnings-1.26B-948.58M-701.28M-485.49M-311.20M-193.17M-112.30M-59.77M-28.93M—
Total Debt83.31M46.38M44.81M28.65M0—9.80M———
Net Cash (Debt)185.58M437.43M375.86M554.74M395.65M476.30M158.75M134.81M61.55M20.67M
Shares Outstanding82.72M77.09M61.42M56.68M47.34M46.57M36.67M31.66M5.01M—

This table shows 10 annual periods of Replimune Group's balance sheet, from FY 2026 back to FY 2017, across 15 line items including cash & equivalents, short-term investments, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow REPL's reporting calendar. What is a balance sheet?

More financial data